# Bioorthogonal Post-Labeling Reveals Nuclear Localization of a Highly Cytotoxic Half-sandwich Ir(III) Tetrazine Complex in Live Cells

Alfonso Annunziata, Sadek Amhaz, Jérémy Forté, Geoffrey Gontard, Romain Morichon, Joëlle Sobczak-Thépot, Michele Salmain

<figure><img src="image_1.png" /></figure>

## ► To cite this version:

Alfonso Annunziata, Sadek Amhaz, Jérémy Forté, Geoffrey Gontard, Romain Morichon, et al. Bioorthogonal Post-Labeling Reveals Nuclear Localization of a Highly Cytotoxic Half-sandwich Ir(III) Tetrazine Complex in Live Cells. ChemBioChem, 2025, 26 (12), pp.e202500090. 10.1002/cbic.202500090. hal-05020776

HAL Id: hal-05020776

https://hal.science/hal-05020776v1

Submitted on 21 Nov 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_3.png" /></figure>

# Bioorthogonal Postlabeling Reveals Nuclear Localization of a Highly Cytotoxic Half-Sandwich Ir(III) Tetrazine Complex in Live Cells

Alfonso Annunziata, Sadek Amhaz, Jérémy Forté, Geoffrey Gontard, Romain Morichon, Joëlle Sobczak-Thépot,* and Michèle Salmain*

Intracellular imaging of anticancer metallodrugs often relies on prelabeling with organic fluorophores, which significantly affects their physicochemical properties and intracellular distribution. On the other hand, the reported postlabeling strategies based on click-chemistry reactions require cell fixation and permeabilization. Here, this study presents a postlabeling approach based on the catalyst-free, inverse electron-demand Diels-Alder reaction (iEDDA) between a strained fluorescein-tagged bicyclononyne derivative (BCN-FAM) and half-sandwich Ir(III) complexes containing bidentate ligands comprising a tetrazine (Tz-R,R') entity. Five half-sandwich Ir(III) complexes with formula [Cp\*Ir(Tz-R,R')Cl]^{0/+} have been synthesized and fully characterized, including the X-ray crystal structures of three

of the five derivatives. Investigations of their stability and their reactivity in aqueous solution and in a model iEDDA reaction reveal the strong influence of the tetrazine ligand structure on the chemical properties of the corresponding complexes. A highly cytotoxic metallodrug candidate (Ir-C,N<sub>Ph,Me</sub>) is identified from biological studies, and chemical reactivity studies disclose an unusual preference for binding of methionine over cysteine. *Postlabeling of Ir-C,N<sub>Ph,Me</sub> in live HeLa cells* highlights its preferential accumulation within the nucleus, suggesting its retention through covalent modifications of nuclear proteins in good agreement with other half-sandwich iridium(III) complexes.

## 1. Introduction

The remarkable success of cisplatin as an anticancer drug[1] has paved the way to explore other transition metal complexes for therapeutic purposes.[2] Over the last decades, novel complexes of Pt,[3-6] Ru,[7,8] Au,[9,10] Ir,[11,12] and Os[13,14] have been proposed as anticancer metallodrug candidates. Among them, half-sandwich

iridium(III) complexes of general formula [(η<sup>5</sup>-Cp<sup>R</sup>)Ir(X-Y)Z], (Cp<sup>R</sup> = cyclopentadienyl derivative, X-Y = bidentate ligand, and Z = monodentate ligand) showed remarkable antiproliferative activity on cell cultures[15-18] and mouse tumor models.[19] The nature of the X-Y and the Cp<sup>R</sup> ligands in this structure has been found to drive both the chemical reactivity and the biological activity of the resulting compounds.[20,21] Indeed, depending on the nature of the X-Y ligand, the corresponding complexes were found to target different cellular organelles and interact with different biological targets, as DNA,[22] proteins,[23] and redox active biomolecules.[24] In general, studying the chemical reactivity in physiological condition, uncovering the intracellular localization, and identifying the possible biochemical targets are key aspects to be disclosed when a new metallodrug candidate is designed.[25]

The most popular strategy to track a nonfluorescent metal complex inside cells involves its conjugation to an organic fluorophore.[26] Some representative examples of fluorescent half-sandwich Ir(III) conjugates are reported in **Figure 1**.

Do and coworkers reported three half-sandwich iridium complexes with picolinamide-BODIPY-conjugate ligands (I in Figure 1) for in-cell transfer hydrogenation.[27] The three derivatives distribute in mitochondria and lysosomes. Similarly, preferential mitochondrial accumulation was observed for Ir(N,O-BODIPY) complexes (II in Figure 1).[28] Noteworthy, the same distribution was observed for (η<sup>6</sup>-p-cymene)Ru(II) and Cp\*Rh(III) derivatives bearing a BODIPY-tagged ligand. Coumarin and rhodamine were also used for conjugation, as in Cp<sup>R</sup> coumarin-salicylaldehyde Schiff base containing compounds[29] (III in Figure 1) and a

A. Annunziata, J. Forté, G. Gontard, M. Salmain
Institut Parisien de Chimie Moléculaire (IPCM)
Sorbonne Université, CNRS
F-75005 Paris, France
E-mail: michele.salmain@sorbonne-universite.fr

A. Annunziata
Nanosciencia
Faraday 9, 28049 Madrid, Spain

S. Amhaz, R. Morichon, J. Sobczak-Thépot
Centre de Recherche Saint Antoine (CRSA)
INSERM, Sorbonne Université
F-75012 Paris, France
E-mail: joelle.sobczak@inserm.fr

S. Amhaz
Chimie Physique et Chimie du Vivant (CPCV), ENS, CNRS
PSL University
Sorbonne Université
F-75005 Paris, France

<figure><img src="image_4.png" /></figure>

Supporting information for this article is available on the WWW under https://doi.org/10.1002/cbic.202500090

<figure><img src="image_5.png" /></figure>

© 2025 The Author(s).ChemBioChem published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
<figure><img src="image_6.png" /></figure>

<figure><img src="image_7.png" /><figcaption>**Figure 1.** Representative examples of half-sandwich Ir(III) complexes conjugated to organic fluorophores (BODIPY for I, II, and V; coumarin for III; and rhodamine for IV).</figcaption></figure>

rhodamine-conjugated bipyridine complex[30] (IV in Figure 1). Complexes III and IV were found to preferentially accumulate in lysosomes. Most noticeably, the free ligand of complex IV localized in the same cellular compartment, suggesting that the fluorophore itself governed the intracellular localization of the conjugate metallodrug. This trend was also observed with a BODIPY-conjugate 2-phenyl-oxazoline iridium complex[31] (V in Figure 1) that was found to accumulate in the endoplasmic reticulum and in mitochondria and then, due to the hydrophobicity of the BODIPY, to be trapped in lipid droplets and delivered to other cell compartments. These examples evidence how fluorescent reporters, usually highly extended aromatic hydrophobic fragments, markedly influence and in some cases entirely govern the intracellular distribution of anticancer metallodrugs.[32,33] Therefore, alternative strategies to track metal-based drugs inside the cell would be highly beneficial to have a more comprehensive and unbiased picture of their intracellular distribution.

Bioorthogonal chemistry has become an essential tool to study biological systems.[34] The concepts of bioorthogonal chemistry have been successfully applied to metal complexes.[35] Many metal derivatives decorated with alkyne or azide fragments ready for copper-catalyzed azide-alkyne cycloaddition (CuAAC) have been reported.[36] However, the well-known toxicity of Cu(I) catalyst[37] restricts postlabeling by CuAAC to fixed cells.[38,39] One of the most powerful bio-orthogonal reactions is

the [4 + 2]-cycloaddition of 1,2,4,5-tetrazines (Tz-R,R') or 1,2,4-triazines with dienophiles, known as inverse electron demand Diels-Alder (iEDDA) reaction.[40] Due to its high reaction rates in catalyst-free conditions, high selectivity, and biocompatibility, iEDDA has been successfully applied in cell imaging,[41–45] as well as for selective delivery of drugs and radiopharmaceuticals.[46–48] s-Tetrazines make useful ligands for a variety of transition metals[49,50] and have been used as well as 1,2,4-triazines in combination with organometallic scaffolds for biological applications. Lo and coworkers designed octahedral bis-cyclometallated luminesogenic Ru, Ir, and Re complexes incorporating a tetrazine entity acting as a quencher.[51–54] Upon iEDDA reaction with strained alkenes and alkynes in living cells, emission is restored, making these complexes useful imaging probes and photosensitizers. Similarly, Kozhevnikov et al. used triazines as ligands in cyclometallated iridium complexes to produce luminescent antibody bioconjugates.[55,56]

As a part of our research on half-sandwich Ir(III) anticancer metallodrugs, we recently combined CuAAC to cryo-XRF to identify the mitochondria and the actin cytoskeleton as key targets of a complex bearing a 2-phenyl-oxazoline decorated with an azide functionality.[57] In the present study, we intend to exploit the reactivity of tetrazine in iEDDA reactions by including it in bidentate ligands (X–Y) of half-sandwich Ir(III) complexes (Ir-Tz<sub>R,R'</sub> in Scheme 1) and propose a postlabeling strategy to localize them
<figure><img src="image_8.png" /></figure>

<figure><img src="image_9.png" /><figcaption>**Scheme 1.** Postlabeling strategy developed in this work.</figcaption></figure>

in *live cells*. This approach involves the incubation of the nonluminescent iridium complex (Step i) and subsequent iEDDA reaction (Step ii) with a fluorescein-conjugate derivative (BCN-FAM) of **BCN-OH** ((1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethanol)), to finally localize the fluorescein-tagged complex through confocal microscopy (Step iii).

In detail, we synthesized and characterized five novel half-sandwich Ir(III) complexes bearing N-N' pyridyl- (Tz-Py,R) or N-C⁻ phenyltetrazines (Tz-Ph,R) as X-Y chelating ligands. We studied their chemical reactivity in coordinating solvents and aqueous solution, and then in iEDDA reaction, as well as their biological properties. Collected results are discussed to rationalize how the different tetrazine ligands affect the chemical reactivity and biological properties of the complexes. Fluorescent postlabeling by iEDDA reaction of the highly cytotoxic derivative Ir-C, N<sub>Ph,Me</sub> allowed to visualize and localize it in both *live* and fixed HeLa cells.

## 2. Results and Discussion

### 2.1. Synthesis and Characterization

The iridium complexes were synthesized according to the procedures reported in **Scheme 2**.

The cationic pyridyl compounds Ir-N,N<sub>Py,R</sub> were isolated as hexafluorophosphate salts by reacting the dimeric precursor [IrCp*Cl<sub>2</sub>]<sub>2</sub> with the appropriate ligand Tz-Py,R and subsequent addition of ammonium hexafluorophosphate. The neutral derivatives Ir-C,N<sub>Ph,R</sub> were synthesized via C-H metalation promoted by sodium acetate in methanol. All the products were characterized by mono- and bidimensional NMR techniques (Figure S1-S5, Supporting Information). In the ¹H NMR spectrum of Ir-N,N<sub>Py,R</sub> complexes, a downfield shift of the aromatic protons was observed with respect to the free tetrazine ligands Tz-Py,R. The inequivalence of the two pyridyl substituents (one coordinated to the metal and the other not) in the spectrum of Ir-N, N<sub>Py,Py</sub> confirmed the identity of the mononuclear iridium complex (see note). The occurrence of cyclometallation in Ir-C,N<sub>Ph,R</sub> was evidenced by ¹H-NMR, with the presence of four inequivalent C-H phenyl protons, as expected for an orthocyclometallated product.[58] Also in this case, for the symmetrically substituted Tz-Ph,Ph, two distinct resonance patterns for the non-equivalent phenyl groups were observed in the ¹H- and ¹³C-NMR spectra, respectively, confirming the formation of the mononuclear iridium species. The methyl protons in the Cp* ligands appeared as singlets in the range 1.7-1.9 ppm, while the aromatic C-Me carbons of Cp* resonated as singlets between 90 and 95 ppm in ¹³C-NMR spectra. The identity and the purity of the compounds were further unequivocally assessed by electrospray ionization-high-resolution mass spectrometry (ESI-HRMS), and by RP-HPLC
<figure><img src="image_10.png" /></figure>

<figure><img src="image_11.png" /><figcaption>**Scheme 2.** Synthetic routes to the Ir(III) tetrazine complexes. Procedure A: (i) AcONa (3 eq.), MeOH, RT, 15 min; (ii) Tz-Py,R, RT, 24–72 h. Procedure B: (i) Tz-Py,R, MeOH, RT, 24 h; (ii) NH₄PF₆ (3 eq.).</figcaption></figure>

(Figure S7–S11, Supporting Information). Moreover, the crystal structures of Ir-C,N<sub>Ph,Me</sub>, Ir-N,N<sub>Py,Me</sub>, and Ir-N,N<sub>Py,Py</sub> were solved by X-ray diffraction analysis (Figure 2).

All three compounds display the expected pseudo-octahedral "piano-stool" geometry with the iridium η<sup>5</sup>-bound to the pentam-ethylcyclopentadienyl ligand. The chelating tetrazine and the chlorido ligands occupy the "leg positions" in the coordination sphere. Selected bond distances and angles (Table S3 and S4, Supporting Information) agree with those reported for other half-sandwich Ir(III) derivatives.<sup>[20]</sup> Structural comparison between the analogous methyl-tetrazine derivatives Ir-N,N<sub>Py,Me</sub> and Ir-C, N<sub>Ph,Me</sub> revealed a shorter Ir-centroid distance for the pyridyl com-plex (1.793 vs. 1.831 Å), ascribable to its cationic nature that results in a tighter binding of the anionic cyclopentadienyl ligand. No significative difference was observed in the Ir-Cl bond lengths for the three compounds, while a shorter Ir-N(Tz) distance was observed for Ir-C,N<sub>Ph,Me</sub> with respect to its cationic congener

(2.024(7) vs. 2.058(4) Å). A significantly different angle N(Tz)-Ir-Cl was also found (87.13° vs. 78.59° for Ir-N,N<sub>Py,Me</sub> and Ir-C,N<sub>Ph,Me</sub>, respectively). Comparison between cationic Ir-N,N<sub>Py,Me</sub> and Ir-N,N<sub>Py,Py</sub> revealed no significative differences.

## 2.2. In-Solution Ir-Cl Cleavage

The cleavage of the Ir-Cl bond is generally believed to be the activation step of half-sandwich iridium complexes in biological systems, as the formed aqua-species (Ir-OH<sub>2</sub>) are highly reactive toward biological nucleophiles.<sup>[59]</sup> However, the extent of hydro-lysis and the chemical properties of the resulting solvento species are strictly dependent on the nature of the chelating ligand.<sup>[60]</sup> Therefore, we investigated the cleavage of the Ir-Cl bond for our tetrazine complexes in coordinating organic solvents and in aqueous solutions to evaluate the effect of the tetrazine ligand on solvolysis.

## 2.3. Solvolysis in Organic Solvents

We first investigated the stability of the complexes in pure acetonitrile (MeCN-d<sub>3</sub>) or dimethylsulfoxide (DMSO-d<sub>6</sub>), by <sup>1</sup>H-NMR. These solvents were chosen as MeCN was used in iEDDA reactivity studies and DMSO as vehicle for biological experiments. The same single set of peaks was observed in the <sup>1</sup>H NMR spectrum of the iridium complexes 5 min after dissolution and after 24 h in both MeCN-d<sub>3</sub> or DMSO-d<sub>6</sub>, except for Ir-N,N<sub>Py,Py</sub> that showed two sets of peaks with a ratio 82:18 after 24 h in DMSO-d<sub>6</sub>. Addition of 1 equiv. AgBF<sub>4</sub> to the solutions of the complexes in MeCN-d<sub>3</sub> or DMSO-d<sub>6</sub> after 24 h resulted in a general downfield shift of the proton peaks, consistent with the formation of solvento species (see, e.g., the spectra of Ir-C,N<sub>Ph,Me</sub> in Figure S12–S13, Supporting Information). This indicated that the complexes (except Ir-N,N<sub>Py,Py</sub> in DMSO-d<sub>6</sub>) had not spontaneously undergone Ir-Cl cleavage in DMSO or MeCN in absence of silver salt. The second set of peaks in the <sup>1</sup>H NMR spectrum of Ir-N,N<sub>Py,Py</sub> in DMSO-d<sub>6</sub> was then attributed to the Ir-DMSO adduct (18% conversion). The lack of reactivity, ascribed to the electronic properties of the tetrazine ligand, is notably different from the vast majority of reported half-sandwich Ir(III) metallodrugs that undergo rapid ligand exchange in DMSO,<sup>[61,62]</sup> due to the high affinity of iridium complexes toward DMSO.<sup>[63]</sup>

<figure><img src="image_12.png" /><figcaption>**Figure 2.** Molecular structures of Ir-N,N<sub>Py,Me</sub> (top left), Ir-C,N<sub>Ph,Me</sub> (top right), and Ir-N,N<sub>Py,Py</sub> (bottom). Hydrogen atoms and counterions were omitted for clarity.</figcaption></figure>
<figure><img src="image_13.png" /></figure>

## 2.4. Solvolysis in Aqueous Solution

Aquation was studied for four of the five complexes by ¹H-NMR spectroscopy in acetone-d₆-D₂O mixture (Ir-C,N<sub>Ph,Ph</sub> was disregarded because it precipitates from the solution even with a small percentage of water). Conversions to the corresponding aquo-species are reported in Table 1, column I.

While, the neutral compound Ir-C,N<sub>Ph,Me</sub> underwent partial aquation with a conversion of 11% after 24 h, almost no aquation of the cationic counterpart Ir-N,N<sub>Py,Me</sub> was detected over several days, even when dissolved in acetone-d₆/D₂O 1:4 mixture. Thus, electronic factor related to the N-N/N-C⁻ ligands seem to affect the Ir-Cl bond strength. The two other pyridyl complexes, Ir-N, N<sub>Py,Ph</sub>, and Ir-N,N<sub>Py,Py</sub> underwent partial to total aquation. Thus, the extent of aquation is greatly influenced by substitution patterns on the tetrazine ligand and appears to be related to the electron-withdrawing strength of the R substituent in Tz-Py,R ligands (Me < Ph < Py).

We next studied the Ir-Cl bond cleavage in DMSO-d₆-D₂O mixture, and results are reported in Table 1, column II. Interestingly, the Ir-DMSO and not Ir-OH₂ adducts were formed for all the complexes (Figure S14-S15, Supporting Information). Complete conversion to the DMSO-species was slowly reached, as Ir-C,N<sub>Ph,Me</sub> gave rise to 67% conversion after 24 h and >95% after 48 h. In the Ir-N,N<sub>Py,R</sub> complexes series, conversion to the DMSO adducts followed the same trend as that observed above for the formation of the aquo-complexes, with complete conversion observed over several days and rate of conversion following the trend Me ≈ Ph << Py. Increased conversion to the DMSO adduct of Ir-N,N<sub>Py,Me</sub> (76% vs. 37%) was observed in DMSO-d₆-D₂O (1:4) after 24 h. In a nutshell, water appears necessary to trigger the cleavage of the Ir-Cl bond, possibly owing to the increased polarity of the medium that favors the ionization. These results also suggest that the aquo-complexes are transient intermediates, as similarly observed in Os(II) half-sandwich metallodrugs.<sup>[64]</sup>

As cell culture media contain a high concentration of chloride (≈150 mM),<sup>[20]</sup> we finally studied the effect of chloride concentration on the formation of the DMSO adducts. To this purpose, the ¹H NMR spectra of the complexes were collected in acetone-d₆/D₂O containing 10% DMSO (acetone was necessary for solubility reasons) or in the same medium supplemented with 150 mM

NaCl. As shown in Table 1, column III, almost quantitative conversion of Ir-N,N<sub>Py,Py</sub> to its DMSO adduct still occurred, confirming once again that the pyridyl substituent made the Ir-Cl bond more labile, while the conversion to the Ir-DMSO adducts was reduced by half for the three other complexes.

## 2.5. iEDDA Reactivity

### 2.5.1. Kinetic Constant Measurement

To understand how the coordination environment of the newly synthesized half-sandwich complexes influences the reactivity of the tetrazine ligand in iEDDA, we measured the second order kinetic constants (k₂) of the reaction with BCN-OH as a model dienophile in MeCN, under pseudo-first-order conditions by ultraviolet-visible spectroscopy (Figure S16-S21, Supporting Information).

All the compounds react with BCN-OH to afford the corresponding Ir-pdz<sub>R,R</sub> complexes where pdz is a pyridazine ligand as confirmed by ESI-HRMS. Cationic pyridyl complexes Ir-N, N<sub>Py,R</sub>, display very high reaction rates with second-order rate constants (k₂, column I in Table 2) between 45.3 ± 0.5 and 286 ± 12 M⁻¹ s⁻¹. The accelerating effect follows the trend Me < Ph < Py and is related to the electron-withdrawing properties of the R substituent, which makes the tetrazine core more electron-deficient and thus more reactive.<sup>[65,66]</sup> The same trend is observed for the free tetrazines (k₂Tz column II in Table 2), measured for comparison. The net positive charge of the Ir-N,N<sub>Py,R</sub> complexes results in a marked accelerating effect of the reaction rate, with k₂/k₂Tz ratios (column III, Table 2) between 16 and 34, following the R substituent trend Py < Ph < Me.<sup>[65,66]</sup> In terms of frontier molecular orbitals, the major contribution in iEDDA reaction arises from the interaction of the LUMO of the tetrazine with HOMO of the BCN-OH dienophile.<sup>[67]</sup> Coordination of the cationic metal center lowers the energy of the LUMO<sup>[68]</sup> for Ir-N,N<sub>Py,R</sub> complexes, resulting in increased reaction rates, yet this stabilization appears higher for Ir-N,N<sub>Py,Me</sub> than for Ir-N,N<sub>Py,Ph</sub> and Ir-N,N<sub>Py,Py</sub>. Distortion energies and intramolecular repulsive interactions also play a key role in the iEDDA reactivity of tetrazines.<sup>[69]</sup> Coordination to the metal scaffold may change the intramolecular motion and interactions of the tetrazine that might be

<table><caption>Table 1. Conversion of the Ir-complexes ([Ir] = 5 mM) to the solvento species in different conditions measured by integration of ¹H NMR peaks; conversion was measured after 24 h at room temperature.</caption><thead><tr><th></th><th>I</th><th>II</th><th>III</th></tr><tr><th>Solvent mix</th><td>Acetone-d<sub>6</sub>/D<sub>2</sub>O<sup>a)</sup></td><td>DMSO-d<sub>6</sub>/D<sub>2</sub>O<sup>a)</sup></td><td>Acetone-d<sub>6</sub>/D<sub>2</sub>O (150 mM NaCl) + 10% DMSO-d<sub>6</sub></td></tr><tr><th>Complex</th><td>% Ir-D<sub>2</sub>O</td><td>% Ir-DMSO</td><td>% Ir-DMSO</td></tr></thead><tbody><tr><td>Ir-C,N<sub>Ph,Me</sub></td><td>11%</td><td>67%<sup>b)</sup></td><td>32% (15%)<sup>d)</sup></td></tr><tr><td>Ir-N,N<sub>Py,Py</sub></td><td>>95%</td><td>>95%</td><td>>95% (>95%)</td></tr><tr><td>Ir-N,N<sub>Py,Ph</sub></td><td>30%</td><td>41%</td><td>38% (23%)</td></tr><tr><td>Ir-N,N<sub>Py,Me</sub></td><td><5%</td><td>37%</td><td>24% (17%)</td></tr><tr><td></td><td>-</td><td>76%<sup>c)</sup></td><td>-</td></tr></tbody><tfoot><tr><td colspan="4"><sup>a)</sup>1:1 mixture. <sup>b)</sup>acetone-d<sub>6</sub>/D<sub>2</sub>O/DMSO-d<sub>6</sub> 4:3:3. <sup>c)</sup>D<sub>2</sub>O/DMSO-d<sub>6</sub> 4:1. <sup>d)</sup>presence of 150 mM NaCl.</td></tr></tfoot></table>
<figure><img src="image_14.png" /></figure>

<table><caption>**Table 2.** iEDDA second-order rate constants for complexes and respective tetrazine ligands measured at 24 °C in MeCN.</caption><thead><tr><th>Complex</th><th>k<sub>2</sub> (M<sup>-1</sup>.s<sup>-1</sup>)</th><th>k<sub>2Tz</sub> (M<sup>-1</sup>.s<sup>-1</sup>)</th><th>k<sub>2</sub>/k<sub>2Tz</sub></th></tr></thead><tbody><tr><td>Ir-N,N<sub>Ph</sub>Py</td><td>286 ± 12</td><td>18 ± 3</td><td>16</td></tr><tr><td>Ir-N,N<sub>Ph</sub>Ph</td><td>80 ± 6</td><td>4.5 ± 0.2</td><td>18</td></tr><tr><td>Ir-N,N<sub>Ph</sub>Me</td><td>45.3 ± 0.5</td><td>1.31 ± 0.01</td><td>34</td></tr><tr><td>Ir-C,N<sub>Ph</sub>Ph</td><td>0.732 ± 0.004</td><td>1.6 ± 0.2</td><td>0.46</td></tr><tr><td>Ir-C,N<sub>Ph</sub>Me</td><td>0.57 ± 0.01</td><td>0.70 ± 0.08</td><td>0.81</td></tr><tr><td>[Ir-C,N<sub>Ph</sub>Me<sup>-</sup>MeCN]<sup>+</sup></td><td>1.8 ± 0.2</td><td>0.70 ± 0.08</td><td>2.6</td></tr><tr><td>[Ir-C,N<sub>Ph</sub>Me<sup>-</sup>MeCN]<sup>+</sup></td><td>6.6 ± 0.7</td><td>-</td><td>-</td></tr></tbody><tfoot><tr><td colspan="4"><sup>a)</sup>in MeCN/H<sub>2</sub>O 1:1.</td></tr></tfoot></table>

responsible for the higher relative increase in the reaction rate observed for Ir-N,N<sub>Ph</sub>Me compared to the two other derivatives.

Neutral Ir-C,N<sub>Ph,R</sub> complexes display up to 500-fold lower second-order rate constants compared to those of Ir-N,N<sub>Ph,R</sub>. The R substituent trend is similar to that reported above for Ir-N,N<sub>Ph,R</sub> with Me < Ph, again ascribable to the electron-withdrawing effect of the substituent. Moreover, $k_2/k_{2Tz} < 1$, indicating slower reaction rates for the complexes compared to the uncoordinated ligands. This effect is due to the negatively charged N,C<sup>-</sup> nature of the ligand, which likely results in the energy increase of the LUMO leading to slower reaction rates. Noteworthy, this effect is more evident in Ir-C,N<sub>Ph,Ph</sub> ($k_2/k_{2Tz} = 0.46$) than in Ir-C,N<sub>Ph,Me</sub> ($k_2/k_{2Tz} = 0.81$), suggesting that the methyl substituent on the tetrazine ring has again a relative beneficial effect on the reactivity of the complex. These results demonstrate that the substitution pattern of the tetrazine core has an impact on the iEDDA reaction rate. However, the charge and the electronic factors remain the major factors contributing to the reactivity of the complexes. To prove it, the cationic acetonitrile derivative [Ir-C,N<sub>Ph,Me</sub>-MeCN]<sup>+</sup> (see Figure in Table 2) was formed in situ by treating Ir-C, N<sub>Ph,Me</sub> with AgBF<sub>4</sub> in acetonitrile. The positive charge at the metal is supposed to lower the energy of the LUMO and increase the reaction rate.[53] Indeed, a threefold higher rate constant ($k_2 = 1.8 M^{-1} s^{-1}$) was measured when [Ir-C,N<sub>Ph,Me</sub>-MeCN]<sup>+</sup> was reacted with BCN-OH. Finally, we performed the reaction between [Ir-C,N<sub>Ph,Me</sub>-MeCN]<sup>+</sup> and BCN-OH in MeCN/H<sub>2</sub>O 1:1, to validate the use of our complexes in the iEDDA-based post-labeling strategy in biological systems. Indeed, the presence of

water in the reaction medium was reported to increase the iEDDA reaction rates.[70] Gratifyingly, we measured a second-order rate constant MeCN/H<sub>2</sub>O 1:1 to be $k_2 = 6.6 M^{-1} s^{-1}$ for [Ir-C,N<sub>Ph,Me</sub>-MeCN]<sup>+</sup>. The collected results evidenced that cationic Ir-N,N<sub>Ph,R</sub> complexes are very valid bioorthogonal probe candidates for fluorescence labeling, as the already high $k_2$ measured in acetonitrile are expected to be even higher when the reaction is performed in biological systems, where fast reactions are necessary to ensure selectivity in the labeling process.[40] However, despite the lower $k_2$ values measured in acetonitrile, Ir-C,N<sub>Ph,R</sub> complexes could benefit from the accelerating effect of water along with the formation of cationic adducts in aqueous solution (as described for DMSO in the previous section), making them good candidates for bioorthogonal labeling as well. Overall, the collected data warrant the application of all our half-sandwich Ir(III) tetrazine complexes for in-cell labeling.

## 2.6. Biological Studies

The cytotoxic activity of the half-sandwich Ir(III) compounds was examined in two human cancer cell lines, Huh-7 (human hepatocellular carcinoma) and HeLa (late-stage cervix carcinoma), by a label-free viability assay based on impedance readout, using the real-time cell analysis (RTCA) system (Figure S22 and S23, Supporting Information).[62,71] Ir-C,N<sub>Ph,Ph</sub> was excluded from this study because of its poor solubility in the experimental conditions. Note: according to the speciation studies detailed below,
<figure><img src="image_15.png" /></figure>

the complexes were administered as their monocationic or dicationic DMSO adducts. IC₅₀ values after 72 h incubation were calculated from the proliferation curves and reported in column I of **Table 3**.

The IC₅₀ values show a contrasting behavior of Ir-C,N<sub>Ph,Me</sub> with respect to the Ir-N,N<sub>Py,R</sub> complexes. Indeed, the three Ir-N,N<sub>Py,R</sub> compounds were found to be inactive up to 10 and 40 µM on the growth of Huh7 and HeLa cells, respectively. Conversely, Ir-C,N<sub>Ph,Me</sub> was highly cytotoxic toward both cell lines, with calculated IC₅₀ = 0.20 ± 0.02 and 0.30 ± 0.01 µM on HeLa and Huh7, respectively. Liu and coworkers reported several families of Ir(III) complexes with different X-Y ligands displaying IC₅₀ spanning over a wide range of 1–100 µM.[18,72–76] 2-Phenyl-oxazoline Ir(III) complexes reported by our group display good cytotoxic potencies in the range of 3–6 µM.[62] Brabec et al.[15] and Pizarro et al.[61] reported highly potent half-sandwich Ir(III) complexes with IC₅₀ values from 0.05 to 0.22 µM toward different cancer cell lines. Within this frame, Ir-C,N<sub>Ph,Me</sub> is among the most potent half-sandwich Ir(III) complexes reported so far.

To better understand the huge difference in the cytotoxic potency displayed by our complexes, we evaluated the lipophilicity of the DMSO adducts by measuring the LogP values (water-octanol partition coefficient, column II in Table 3). Ir-N, N<sub>Py,R</sub> complexes all display LogP < 1, indicative of a hydrophilic character. Conversely, for complexes Ir-C,N<sub>Ph,R</sub>, LogP values of 3.7 and 4.7 were measured for Ir-C,N<sub>Ph,Me</sub> and Ir-C,N<sub>Ph,Ph</sub>, respectively. These values indicate a hydrophobic character, logically increasing from the methyl to the phenyl derivative. Such striking difference is expected to affect the cell permeability of the complexes,[77,78] which could explain the lack of cytotoxicity observed for Ir-N,N<sub>Py,R</sub> complexes. To confirm this hypothesis, we measured by inductively coupled plasma optical emission spectroscopy (ICP-OES) the content of iridium in HeLa cells treated with Ir-C, N<sub>Ph,Me</sub> and Ir-N,N<sub>Py,Me</sub> for 30 min (Table 3). Taking a mean volume of 3700 µm³ for a single HeLa cell, the respective concentration of elemental iridium in cells treated with 2 µM complex was 57 µM for Ir-N,N<sub>Py,Me</sub> and 8280 µM for Ir-C,N<sub>Ph,Me</sub>. This latter value illustrates the "sponge-like" effect[79] exerted by the cells toward Ir-C, N<sub>Ph,Me</sub>. This excellent cell permeability is probably one of the factors for the high cytotoxic potency of Ir-C,N<sub>Ph,Me</sub> and the lack of cytotoxic activity of Ir-N,N<sub>Py,Me</sub>.

## 2.7. Speciation in Biological Medium

Biological studies determined Ir-C,N<sub>Ph,Me</sub> as the best anticancer metallodrug candidate, owing to its high cytotoxicity. To gain further insight into its remarkable potency, we studied by HPLC and ESI-HRMS its speciation in biological media[80] in the presence of DMSO, used as vehicle for cell experiments, and its chemical reactivity with potential biological targets. The nontoxic methyl substituted analog Ir-N,N<sub>Py,Me</sub> was also studied to evaluate whether a different chemical behavior could explain its lack of cytotoxicity.

Speciation of Ir-C,N<sub>Ph,Me</sub> (50 µM) in different media was investigated by RP-HPLC (Figure S24, Supporting Information). In H₂O/MeOH 95:5, the corresponding chromatograms recorded at 0 and 3 h showed two peaks at t<sub>R</sub> = 4.1 and 15.6 min, respectively, assigned to the aquo and chlorido complexes. A 68% conversion to the aquo complex was determined from peak areas after 3 h (Table S1, Supporting Information). Addition of 1 mM DMSO (0.007% v/v) gave rise to a mixture of Ir-DMSO (t<sub>R</sub> = 3.0 min) and Ir-OH₂ (t<sub>R</sub> = 4.1 min) adducts in 7/93 ratio after 40 min and the disappearance of the starting chlorido complex (Figure S24B, Supporting Information). Such results support the hypothesis that the aquo species is an intermediate in the DMSO coordination process. Replacement of water by PBS suppressed the hydrolysis (Figure S24C, Supporting Information) and addition of DMSO (0.007% v/v) gave rise to a mixture of the chlorido, aquo, and DMSO complexes in the proportion 75/9/16. Increasing the amount of DMSO up to 0.1% (13 mM) completely shifted the overall equilibrium in favor of the DMSO adduct (Figure S24D, Supporting Information).

Next, the formation of [Ir-C,N<sub>Ph,Me</sub>-DMSO]<sup>+</sup> was checked in serum-free cell culture medium (DMEM, **Figure 3**). Upon dilution to 10 µM of a stock DMSO solution in DMEM to final 0.1% DMSO v/v (Ir/DMSO = 1:1500 mol mol⁻¹, i.e., conditions matching those used in cell administration), only the peak at 3.0 min previously assigned to the DMSO adduct was observed within 30 min while the peak at 15.3 min disappeared, in agreement with previous observations in PBS. Conversion of Ir-C,N<sub>Ph,Me</sub> to the DMSO adduct indicates that the starting chlorido complex may not the biologically active species taken up by the cells, and Ir—Cl bond cleavage is the activation step of this metallodrug.[81]

<table><caption>**Table 3.** Partition coefficients, quantities of iridium in HeLa cells after 30 min assayed by ICP-OES and IC₅₀ values measured at 72 h by RTCA (see legend of Figure S26, supporting information).</caption><thead><tr><th rowspan="3">Complex</th><th colspan="2">I</th><th rowspan="2">II</th><th rowspan="3">Log P</th></tr><tr><th colspan="2">IC<sub>50</sub> [µM]</th></tr><tr><th>HeLa</th><th>Huh-7</th><th>Iridium quantity [ng/10<sup>6</sup> cells]</th></tr></thead><tbody><tr><td>Ir-N,N<sub>Py,Me</sub></td><td>&gt;40</td><td>&gt;10</td><td>4 ± 0.1<sup>a)</sup><br>17.0 ± 0.4<sup>b)</sup></td><td>&lt;1</td></tr><tr><td>Ir-N,N<sub>Py,Py</sub></td><td>&gt;40</td><td>&gt;10</td><td>N.D.</td><td>&lt;1</td></tr><tr><td>Ir-N,N<sub>Py,Ph</sub></td><td>&gt;40</td><td>&gt;10</td><td>N.D.</td><td>&lt;1</td></tr><tr><td>Ir-C,N<sub>Ph,Me</sub></td><td>0.20 ± 0.02</td><td>0.30 ± 0.01</td><td>42.0 ± 0.5<sup>c)</sup><br>578.0 ± 2.3<sup>a)</sup></td><td>3.7</td></tr></tbody></table>

<footnote>a) Cells incubated with 2 µM complex. b) Cells incubated with 20 µM complex; and c) Cells incubated with 0.2 µM complex.</footnote>
<figure><img src="image_16.png" /></figure>

<figure><img src="image_17.png" /><figcaption>**Figure 3.** HPLC traces of Ir-C,N<sub>Ph,Me</sub> (10 µM in DMEM + 0.1% DMSO) immediately after dilution and after 30 min at room temperature. The intense peak observed around t<sub>R</sub> = 2 min is due to DMEM components.</figcaption></figure>

When this set of experiments was performed with Ir-N,N<sub>Py,Me</sub> only the chlorido complex could be detected by HPLC, while the aqua or DMSO adducts were not retained in any of the tested elution conditions, probably due to their dicationic nature.

We previously observed that other half-sandwich iridium complexes bind to a wide set of cellular proteins.[57] Therefore, to get insight into the possible molecular target(s) of Ir-C, N<sub>Ph,Me</sub>, we investigated its reactivity with model amino acids (AA), namely N-acetyl-L-histidine (His), N-Boc-L-methionine (Met), and N-acetyl-L-cysteine methyl ester (Cys). The formation of the iridium-amino acid adducts was first monitored by HPLC after 2 h incubation in H₂O/MeOH 7:3 at 37 °C. The appearance of new peaks in the chromatogram suggested the formation of covalent adducts (Figure S25, Supporting Information). ESI-HRMS analysis of the reaction mixtures (Figure S26–S28, Supporting Information) confirmed that cationic adducts of type [Ir-C,N<sub>Ph,Me</sub>-AA]<sup>+</sup> were formed with His, Cys, and Met by replacement of the chlorido ligand. In contrast, mass spectrometry analysis of mixtures of Ir-N,N<sub>Py,Me</sub> and AA showed no binding to Met, while adducts with His and Cys were detected (Figure S29–S30, Supporting Information). At this point, we questioned whether the DMSO adduct reacted similarly with the considered amino acids in DMEM. To investigate this aspect, [Ir-C,N<sub>Ph,Me</sub>-DMSO]<sup>+</sup> was formed in situ by dilution of a DMSO solution of Ir-C, N<sub>Ph,Me</sub> in DMEM and then incubated with each amino acid at 37 °C for 2 h (Figure S31, Supporting Information). In these

conditions, only the sulfur-containing derivatives Cys and Met were able to displace coordinated DMSO and form [Ir-C,N<sub>Ph,Me</sub>-AA]<sup>+</sup> adducts, while no His adduct was observed. Furthermore, a competitive binding experiment with an equimolar mixture of the three amino acids for 2 h at 37 °C showed again the preferential formation of adducts with S-containing amino acids, along with persistence of the DMSO species (Figure S32, Supporting Information). By integration of the peaks areas, the Ir-Met-to-Ir-Cys ratio was 3:1, suggesting an unusual preferential binding to methionine over cysteine.[82] This selectivity may in turn have a strong impact on the biological properties of the complex, by targeting specific cellular protein targets as surface-accessible, reactive methionines are limited.[83] Indeed, S-donor amino acids are very frequent binding sites for metal complexes in several proteins identified as possible targets for anticancer metallodrugs.[84,85] Methionine binding has been involved in the interaction of metal complexes with several proteins[25] such as human serum albumin[86] and Ctr1, a Cu-transporter already involved in the cellular uptake of cisplatin.[87] On the other hand, the lack of reactivity of Ir-N,N<sub>Py,Me</sub> toward methionine suggests a different set of biomolecular interactions with cellular proteins, and this is another factor, along with the LogP < 1 that could explain its very low cellular uptake and cytotoxicity. Overall, such results provide useful information to guide the identification of the biochemical targets of this tetrazine complex.

Overall, our speciation studies evidence that, upon administration, [Ir-C,N<sub>Ph,Me</sub>-DMSO]<sup>+</sup> is formed and accumulates inside cells. However, reaction with biological S-nucleophiles present in the culture medium to form covalent adducts that can also enter the cells by passive diffusion or active transport cannot be ruled out.[88]

## 2.8. Reactivity with the Bio-orthogonal Fluorescent Reagent BCN-FAM

We next selected Ir-C,N<sub>Ph,Me</sub> as candidate for the postlabeling iEDDA-based strategy. Indeed, this highly cytotoxic metallodrug displayed an excellent cell permeability, and we proved that it undergoes Ir-Cl cleavage to form cationic adducts in aqueous systems. These factors are likely to increase the iEDDA reaction rate, supporting selective and efficient bioorthogonal in-cell labeling. We synthesized a BCN-OH fluorescein conjugate, BCN-FAM (Scheme 1) as bioorthogonal labeling reagent, following a procedure reported in the literature (Figure S6, Supporting Information).[89] Before moving to cell experiments, we tested the iEDDA labeling strategy in vitro.

Reaction between Ir-C,N<sub>Ph,Me</sub> and 2.5 eq. of BCN-FAM in methanol at room temperature afforded the pyridazine product Ir-pdz<sub>Ph,Me</sub>-FAM as a mixture of two diasteroisomers, due to the presence of stereogenic centers on the metal and BCN-FAM with an observed rate constant of 0.017 min⁻¹ and a half-life of 41 min, as monitored by HPLC (Figure S32, Supporting Information). By comparison, Ir-N,N<sub>Py,Me</sub> reacts faster with BCN-FAM, with 54% conversion measured at the first injection (Figure S33, Supporting Information), consistently with the kinetic studies performed on BCN-OH. The identity of the
<figure><img src="image_18.png" /></figure>

two pyridazine products Ir-pdz<sub>R,R</sub>-FAM was confirmed by ESI-HRMS analysis, which showed no other species formed upon reaction. Then, we performed the reaction between Ir-C, N<sub>Ph,Me</sub> and BCN-FAM in cell culture medium (DMEM) containing 1% DMSO. According to the speciation studies, in this condition [Ir-C,N<sub>Ph,Me</sub>-DMSO]<sup>+</sup> is the only species present in solution. In these conditions, Ir-C,N<sub>Ph,Me</sub> reacts much faster than in MeOH, with 91% of the starting material converted to the pyridazine product at the first injection (<5 min) at room temperature, selectively forming Ir-pdz<sub>Ph,Me</sub>-FAM as a mixture of the two diasteroisomers, as detected by HPLC and HRMS (Figure S34, Supporting Information).

Once we proved the formation of the desired labeled product Ir-pdz<sub>R,R</sub>-FAM, we measured their fluorescence spectrum in different solvent mixtures (Figure S35, Supporting Information). To this purpose, the reaction between Ir-C,N<sub>Ph,Me</sub> or Ir-N,N<sub>Py,Me</sub> and BCN-FAM was repeated in methanol or acetonitrile using an excess of the iridium complexes to fully consume BCN-FAM and measure only the fluorescence emission of the Ir-pdz<sub>R,R</sub>-FAM products. Both labeled compounds showed an emission profile similar to that of BCN-FAM with λ<sub>em</sub> in the range of 519-525 nm, with a slight change according to the solvent mixture (methanol, water + 1% DMSO, and DMEM + 1% DMSO were examined). The robust emission of the iEDDA product at 519 nm in DMEM + 1% DMSO, along with the fast and selective ligation in pseudo-physiological conditions, comforts the translation of the postlabeling strategy to live cells.

## 2.9. In-Cell Fluorescence Labeling

The ability of Ir-C,N<sub>Ph,Me</sub> to undergo iEDDA reaction with BCN-FAM was then examined in live cells. Ir-N,N<sub>Py,Me</sub> was also tested for comparison. HeLa cells were incubated with the complexes for 30 min and then washed with PBS. Then, cells were further incubated for 4 h with medium containing BCN-FAM (8 µM) and washed thoroughly with DMEM prior to confocal microscopy. A minimal concentration of 2 µM of Ir-C,N<sub>Ph,Me</sub> was required to acquire good quality images with BCN-FAM, but no cytotoxic effects were detected during this brief exposure time, while BCN-FAM itself was not toxic up to 40 µM. Interestingly, a strong green fluorescence emission was readily detected in live cells (Figure 4), attributable to the labeled complex Ir-pdz<sub>Ph,Me</sub>-FAM.

Confocal fluorescence images show a robust staining of the complex in the nucleus except darker areas corresponding to nuclear bodies, such as nucleoli. Only a faint staining was detected in the cytoplasm (Figure 4). These results were reproduced in cells that were fixed prior to iEDDA labeling (Figure S36, Supporting Information). This method enhanced the cytoplasmic staining but again showed a significant colocalization of Ir-C,N<sub>Ph,Me</sub> labeled with BCN-FAM and the blue-fluorescent DNA stain DAPI (Pearson's correlation coefficient 0.62 ± 0.06). No fluorescence signal was detected in cells pretreated with only DMSO vehicle or Ir-N,N<sub>Py,Me</sub> and then incubated with BCN-FAM for 4 h. This confirms that unreacted BCN-FAM is effectively removed by washing, and no unwanted side labeling of biomolecules occurred.[90] The absence of fluorescence signal in cells

<figure><img src="image_19.png" /><figcaption>**Figure 4.** *In vivo* imaging of Ir-C,N<sub>Ph,Me</sub> in HeLa cells using BCN-FAM as a sensor. HeLa cells were sequentially exposed to 2 µM Ir-C,N<sub>Ph,Me</sub> or Ir-N,N<sub>Py,Me</sub> for 30 min, and then to 8 µM BCN-FAM for 4 h. After several washes to remove unbound freely diffusible BCN-FAM, live confocal microscopy was then immediately performed to acquire the fluorescence signal (shown here as the sum of five confocal planes). Cells were also visualized by transmitted light to identify nuclei and nuclear bodies including nucleoli, which appeared darker. A robust fluorescence signal was detected in cells exposed to Ir-C,N<sub>Ph,Me</sub> but not in cells exposed to Ir-N,N<sub>Py,Me</sub> or the DMSO vehicle, indicating the presence of Ir-C,N<sub>Ph,Me</sub> in cells and its tracking with BCN-FAM.</figcaption></figure>
<figure><img src="image_20.png" /></figure>

treated with Ir-N,N<sub>Py,Me</sub> is most likely due to its very poor cell
uptake. These results proved the efficacy of our postlabeling strat-
egy to visualize organometallic complexes in live cells.

Preferential accumulation of Ir-C,N<sub>Ph,Me</sub> in the nucleus of
cells rather than in other cellular organelles may be tricky to
rationalize. Indeed, many factors may affect the subcellular
distribution.[91] As discussed in the introduction, preferential accu-
mulation of iridium complexes in lysosomes and mitochondria
was observed when the metal structures were conjugated to
highly hydrophobic fluorescent reporters,[27-31] whose physico-
chemical properties govern the intracellular distribution of the
whole conjugate species.[32,33] Pizarro and coworkers unambigu-
ously localized a highly cytotoxic cationic pyridine-tethered irid-
ium complex in mitochondria in MCF-7 human breast cancer
cells, by combining cryo-SXT and cryo-XRF tomography techni-
ques.[92] Lipophilic cations are known to preferentially accumulate
into the mitochondria,[93] and in that case the doubly chelate
nature of the tethered complex may confer to the complex
the appropriate lipophilic-charge balance to enter this specific
organelle. Liu and coworkers reported an half-sandwich Ir(III)
complexes with an imino-pyridyl ligand[94] that also accumulates
in the nucleus of A549 lung cancer cells. Notably, the authors
reported a LogP value of 3.5[94] very close to that of Ir-C,N<sub>Ph,Me</sub>.
Therefore, the degree of lipophilicity might be considered a
factor governing the nuclear accumulation of our complex.[91]
Li and coworkers reported some cyclometalated iridium com-
plexes of formula [Ir(C-N)<sub>2</sub>(solv)<sub>2</sub>]<sup>+</sup> (C-N = phenylpyridine deriva-
tive, solv = DMSO, or MeCN) that preferentially accumulate in the
nuclei via protein-mediated transport of the nuclear pore com-
plexes.[95,96] These complexes share with [Ir-C,N<sub>Ph,Me</sub>-DMSO]<sup>+</sup>
the same charge, cyclometalated C-N and DMSO ligands, which
could agree with the interaction with proteins involved in NPCs
transport. Finally, free diffusion to the nucleus and formation of
covalent adducts with nuclear proteins is another mechanism
that could explain retention of Ir-C,N<sub>Ph,Me</sub> in the nucleus, as
we previously showed for a half-sandwich iridium complex.[57]

**3. Conclusions**

To sum up, we have presented a fast and selective in-cell label-
ing strategy of Ir(III) half-sandwich complexes based on the
iEDDA reaction between the Ir-coordinated tetrazine ligand
and a fluorescein-tagged BCN derivative. A library of five com-
plexes featuring a tetrazine-containing neutral N–N or an anionic
N–C⁻ ligand was first produced. Extensive solvolysis studies
underscored that the liability of the chlorido ligand was greatly
influenced by the nature of the chelating ligand and the solvent
composition. Speciation studies in biological medium suggested
that the compounds are administered to the cells as their DMSO
adducts. Further exchange of the DMSO ligand by S-containing
amino acids was demonstrated with an unusual preference for
methionine over cysteine. All the complexes efficiently under-
went iEDDA reaction with a model strained alkyne and parame-
ters governing the rate constant value were duly identified,
underscoring the possibility to tune the chemical reactivity of
the complexes according to the chelating ligand structure.

Biological studies revealed a strong cytotoxicity for Ir-C,N<sub>Ph,Me</sub>, which was identified as one of the most potent iridium-based anticancer metallodrugs reported to date. Its high cytotoxicity was correlated to a remarkable level of cellular accumulation. Finally, in vivo labeling of Ir-C,N<sub>Ph,Me</sub> was successfully demonstrated in live HeLa cells, via confocal fluorescence microscopy and revealed a preferential accumulation of the complex in the nucleus.

Our postlabeling strategy provides a valid approach to track
cytotoxic metal complexes in *live cells* by fluorescence micro-
copy, providing qualitative information on their subcellular distri-
bution and highlights the dual functionality of tetrazine as both
ligand and bioorthogonal reactive entity. In-depth biological
studies are now required to elucidate the mechanism of action
of Ir-C,N<sub>Ph,Me</sub> and establish a precise correlation between its
chemical reactivity, its subcellular distribution and its cytotoxicity.

**4. Notes**

The optimized reaction procedure involves addition of a solu-
tion of [IrCp\*Cl₂]₂ to a solution containing the tetrazine ligand.
Addition of ligand Tz-Py,Py to the solution of Ir dimer resulted
in the formation of a side product beyond complex Ir-N,N<sub>Py,Py</sub>.
Attempts to separate the two compounds led to isolate crystals
that were identified as a bimetallic species according to its X-Ray
diffraction analysis (Figure S37, Supporting Information) that was
not characterized any further.

Acknowledgements

This work was financially supported by the PCSI program of ITMO
Cancer supported by Inserm and Aviesan (grant no. 20CP175-00).
The confocal microscopy platform received financial support
from ITMO Cancer of Aviesan within the framework of the
2021–2030 Cancer Control Strategy on funds administered by
Inserm. The authors acknowledge Benoit Caron and Julie Noël
(ALIPP6 platform, Sorbonne Université) for the ICP-OES measure-
ments and the MS³U platform of Sorbonne Université for the
HRMS analyses.

**Conflict of Interest**

The authors declare no conflict of interest.

Data Availability Statement

Deposition Numbers 2324970 (for Ir-N,N<sub>Py,Me</sub>), 2324971 (for Ir-C,N<sub>Py,Me</sub>), 2324972 (for Ir-N,N<sub>Py,Py</sub>), and 2324973 (for Ir<sub>2</sub>(N,N<sub>Py,Py</sub>)(Cl)<sub>2</sub>) contain the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe. The data that support the findings of this study are available in the supplementary material of this article.
<figure><img src="image_21.png" /></figure>

Keywords: antitumor agents • cellular imaging • fluorescent probes • inverse electron-demand Diels-Alder • iridium • solvolysis • strained alkynes

[1] T. C. Johnstone, K. Suntharalingam, S. J. Lippard, *Chem. Rev.* **2016**, *116*, 3436.

[2] E. Boros, P. J. Dyson, G. Gasser, *Chem* **2020**, *6*, 41.

[3] R. G. Kenny, C. J. Marmion, *Chem. Rev.* **2019**, *119*, 1058.

[4] A. Annunziata, M. E. Cucciolito, R. Esposito, P. Imbimbo, G. Petruk, G. Ferraro, V. Pinto, A. Tuzi, D. M. Monti, A. Merlino, F. Ruffo, *Dalton Trans.* **2019**, *48*, 7794.

[5] A. Annunziata, M. E. Cucciolito, R. Esposito, G. Ferraro, D. M. Monti, A. Merlino, F. Ruffo, *Eur. J. Inorg. Chem.* **2020**, *918*.

[6] A. Annunziata, D. Liberti, E. Bedini, M. E. Cucciolito, D. Loreto, D. M. Monti, A. Merlino, F. Ruffo, *Int. J. Mol. Sci.* **2021**, *22*, 8704.

[7] P. J. Dyson, *Chim. Int. J. Chem.* **2007**, *61*, 698.

[8] T. R. Steel, F. Walsh, A. Wieczorek-Blauž, M. Hanif, C. G. Hartinger, *Coord. Chem. Rev.* **2021**, *439*, 213890.

[9] B. Bertrand, A. Casini, *Dalton Trans.* **2014**, *43*, 4209.

[10] A. Annunziata, G. Ferraro, M. E. Cucciolito, P. Imbimbo, A. Tuzi, D. M. Monti, A. Merlino, F. Ruffo, *Dalton Trans.* **2022**, *51*, 10475.

[11] A. J. Millett, A. Habtemariam, I. Romero-Canelón, G. J. Clarkson, P. J. Sadler, *Organometallics* **2015**, *34*, 2683.

[12] J. M. Hearn, G. M. Hughes, I. Romero-Canelón, A. F. Munro, B. Rubio-Ruiz, Z. Liu, N. O. Carragher, P. J. Sadler, *Metallogics* **2018**, *10*, 93.

[13] Y. Fu, M. J. Romero, A. Habtemariam, M. E. Snowden, L. Song, G. J. Clarkson, B. Qamar, A. M. Pizarro, P. R. Unwin, P. J. Sadler, *Chem. Sci.* **2012**, *3*, 2485.

[14] M. Hanif, M. V. Babak, C. G. Hartinger, *Drug Discov. Today* **2014**, *19*, 1640.

[15] V. Novohradsky, L. Zerzankova, J. Stepanova, A. Kisova, H. Kostrhunova, Z. Liu, P. J. Sadler, J. Kasparkova, V. Brabec, *Metallogics* **2014**, *6*, 1491.

[16] X. Hu, L. Guo, M. Liu, M. Sun, Q. Zhang, H. Peng, F. Zhang, Z. Liu, *Inorg. Chem.* **2022**, *61*, 10051.

[17] L. Guo, P. Li, J. Li, Y. Gong, X. Li, T. Wen, X. Wu, X. Yang, Z. Liu, *Inorg. Chem.* **2023**, *62*, 21379.

[18] L. Guo, P. Li, J. Li, Y. Gong, X. Li, Y. Liu, K. Yu, Z. Liu, *Inorg. Chem.* **2023**, *62*, 15118.

[19] M. Shao, M. Yao, X. Liu, C. Gao, W. Liu, J. Guo, J. Zong, X. Sun, Z. Liu, *Inorg. Chem.* **2021**, *60*, 17063.

[20] Z. Liu, L. Salassa, A. Habtemariam, A. M. Pizarro, G. J. Clarkson, P. J. Sadler, *Inorg. Chem.* **2011**, *50*, 5777.

[21] Z. Liu, I. Romero-Canelón, A. Habtemariam, G. J. Clarkson, P. J. Sadler, *Organometallics* **2014**, *33*, 5324.

[22] Z. Liu, A. Habtemariam, A. M. Pizarro, S. A. Fletcher, A. Kisova, O. Vrana, L. Salassa, P. C. A. Brujinincx, G. J. Clarkson, V. Brabec, P. J. Sadler, *J. Med. Chem.* **2011**, *54*, 3011.

[23] D. Truong, M. P. Sullivan, K. K. H. Tong, T. R. Steel, A. Prause, J. H. Lovett, J. W. Andersen, S. M. F. Jamieson, H. H. Harris, I. Ott, C. M. Weekley, K. Hummitzsch, T. Söhnel, M. Hanif, N. Metzler-Nolte, D. C. Goldstone, C. G. Hartinger, *Inorg. Chem.* **2020**, *59*, 3281.

[24] W.-Y. Zhang, S. Banerjee, G. M. Hughes, H. E. Bridgewater, J.-I. Song, B. G. Breeze, G. J. Clarkson, J. P. C. Coverdale, C. Sanchez-Cano, F. Ponte, E. Sicilia, P. J. Sadler, *Chem. Sci.* **2020**, *11*, 5466.

[25] C. G. Hartinger, M. Groessl, S. M. Meier, A. Casini, P. J. Dyson, *Chem. Soc. Rev.* **2013**, *42*, 6186.

[26] B. Bertrand, K. Passador, C. Goze, F. Denat, E. Bodio, M. Salmain, *Coord. Chem. Rev.* **2018**, *358*, 108.

[27] S. Bose, H. D. Nguyen, A. H. Ngo, L. H. Do, *J. Inorg. Biochem.* **2022**, *234*, 111877.

[28] G. Gupta, P. Kumari, J. Y. Ryu, J. Lee, S. M. Mobin, C. Y. Lee, *Inorg. Chem.* **2019**, *58*, 8587.

[29] C. Liu, X. Liu, X. Ge, Q. Wang, L. Zhang, W. Shang, Y. Zhang, X. A. Yuan, L. Tian, Z. Liu, J. You, *Dalton Trans.* **2020**, *49*, 5988.

[30] W. Ma, L. Guo, Z. Tian, S. Zhang, X. He, J. Li, Y. Yang, Z. Liu, *Dalton Trans.* **2019**, *48*, 4788.

[31] R. Ramos, J.-F. Gilles, R. Morichon, C. Przybylski, B. Caron, C. Botuha, A. Karaiskou, M. Salmain, J. Sobczak-Thépot, *J. Med. Chem.* **2021**, *64*, 16675.

[32] C. A. Puckett, J. K. Barton, *J. Am. Chem. Soc.* **2009**, *131*, 8738.

[33] J. C. Jagodinsky, A. Sulima, Y. Cao, J. E. Poprawski, B. N. Blackman, J. R. Lloyd, R. E. Swenson, M. M. Gottesman, M. D. Hall, *JBIC J. Biol. Inorg. Chem.* **2015**, *20*, 1081.

[34] S. L. Scinto, D. A. Bilodeau, R. Hincapie, W. Lee, S. S. Nguyen, M. Xu, C. W. am Ende, M. G. Finn, K. Lang, Q. Lin, J. P. Pezacki, J. A. Prescher, M. S. Robillard, J. M. Fox, *Nat. Rev. Methods Primer* **2021**, *1*, 30.

[35] M. Salmain, N. Fischer-Durand, B. Rudolf, *Eur. J. Inorg. Chem.* **2020**, *2020*, *21*.

[36] M. G. Ahmad, M. M. Balamurali, K. Chanda, *Chem. Soc. Rev.* **2023**, *52*, 5051.

[37] D. C. Kennedy, C. S. McKay, M. C. B. Legault, D. C. Danielson, J. A. Blake, A. F. Pegoraro, A. Stolow, Z. Mester, J. P. Pezack, *J. Am. Chem. Soc.* **2011**, *133*, 17993.

[38] S. Ding, X. Qiao, J. Suryadi, G. S. Marrs, G. L. Kucera, U. Bierbach, *Angew. Chem. Int. Ed.* **2013**, *52*, 3350.

[39] R. Wirth, J. D. White, A. D. Moghaddam, A. L. Ginzburg, L. N. Zakharov, M. M. Haley, V. J. DeRose, *J. Am. Chem. Soc.* **2015**, *137*, 15169.

[40] B. L. Oliveira, Z. Guo, G. J. L. Bernardes, *Chem. Soc. Rev.* **2017**, *46*, 4895.

[41] N. K. Devaraj, R. Upadhyay, J. B. Haun, S. A. Hilderbrand, R. Weissleder, *Angew. Chem. Int. Ed.* **2009**, *48*, 7013.

[42] K. Lang, L. Davis, J. Torres-Kolbus, C. Chou, A. Deiters, J. W. Chin, *Nat. Chem.* **2012**, *4*, 298.

[43] H. Wu, J. Yang, J. Šečutė, N. K. Devaraj, *Angew. Chem. Int. Ed.* **2014**, *53*, 5805.

[44] X. Shang, X. Song, C. Faller, R. Lai, H. Li, R. Cerny, W. Niu, J. Guo, *Chem. Sci.* **2017**, *8*, 1141.

[45] A. Hamsath, O. L. Lederberg, Q. Cui, M. Shieh, Y. Lam, B. J. Brummett, S. Xu, J. R. Robinson, M. Xian, *Chem. Sci.* **2022**, *13*, 10336.

[46] R. M. Versteegen, R. Rossin, W. ten Hoeve, H. M. Janssen, M. S. Robillard, *Angew. Chem. Int. Ed.* **2013**, *52*, 14112.

[47] R. Rossin, R. M. Versteegen, J. Wu, A. Khasanov, H. J. Wessels, E. J. Steenbergen, W. ten Hoeve, H. M. Janssen, A. H. A. M. van Onzen, P. J. Hudson, M. S. Robillard, *Nat. Commun.* **2018**, *9*, 1484.

[48] M. Vlastara, R. Rossin, F. J. M. Hoeben, K. E. de Roode, M. Boswinkel, L. H. J. Kleijn, J. Nagarajah, M. Rijpkema, M. S. Robillard, *Theranostics* **2023**, *13*, 4004.

[49] O. Stetsiuk, A. Abhervé, N. Avarvari, *Dalton Trans.* **2020**, *49*, 5759.

[50] W. Kaim, *Coord. Chem. Rev.* **2002**, *230*, 127.

[51] T. S.-M. Tang, H.-W. Liu, K. K.-W. Lo, *Chem. Commun.* **2017**, *53*, 3299.

[52] P. K.-K. Leung, L. C.-C. Lee, H. H.-Y. Yeung, K.-W. Io, K. K.-W. Lo, *Chem. Commun.* **2021**, *57*, 4914.

[53] A. M.-H. Yip, C. K.-H. Lai, K. S.-M. Yiu, K. K.-W. Lo, *Angew. Chem. Int. Ed.* **2022**, *61*, e202116078.

[54] J. Shum, L. C.-C. Lee, M. W.-L. Chiang, Y.-W. Lam, K. K.-W. Lo, *Angew. Chem. Int. Ed.* **2023**, *62*, e202303931.

[55] V. N. Kozhevnikov, M. E. Deary, T. Mantso, M. I. Panayiotidis, M. T. Sims, *Chem. Commun.* **2019**, *55*, 14283.

[56] L. Cooke, K. Gristwood, K. Adamson, M. T. Sims, M. E. Deary, D. Bruce, A. N. Antoniou, H. R. Walden, J. C. Knight, T. Antoine-Brunet, M. Joly, D. Goyard, P.-H. Lanoë, N. Berthet, V. N. Kozhevnikov, *Dalton Trans.* **2024**, *53*, 15501.

[57] R. Ramos, A. Karaiskou, C. Botuha, S. Amhaz, M. Trichet, F. Dingli, J. Forté, F. Lam, A. Canette, C. Chaumeton, M. Salome, T. Chenuel, C. Bergonzi, P. Meyer, S. Bohic, D. Loew, M. Salmain, J. Sobczak-Thépot, *J. Med. Chem.* **2024**, *67*, 6189.

[58] D. L. Davies, O. Al-Duajj, J. Fawcett, M. Giardiello, S. T. Hilton, D. R. Russell, *Dalton Trans.* **2003**, *21*, 4132.

[59] F. Wang, A. Habtemariam, E. P. L. van der Geer, R. Fernández, M. Melchart, R. J. Deeth, R. Aird, S. Guichard, F. P. A. Fabbiani, P. Lozano-Casal, I. D. H. Oswald, D. I. Jodrell, S. Parsons, P. J. Sadler, *Proc. Natl. Acad. Sci.* **2005**, *102*, 18269.

[60] E. J. Anthony, E. M. Bolitho, H. E. Bridgewater, O. W. L. Carter, J. M. Donnelly, C. Imberti, E. C. Lant, F. Lermyte, R. J. Needham, M. Palau, P. J. Sadler, H. Shi, F.-X. Wang, W.-Y. Zhang, Z. Zhang, *Chem. Sci.* **2020**, *11*, 12888.

[61] A. C. Carrasco, V. Rodríguez-Fanjul, A. Habtemariam, A. M. Pizarro, *J. Med. Chem.* **2020**, *63*, 4005.

[62] R. Ramos, J. M. Zimbron, S. Thorimbert, L.-M. Chamoreau, A. Munier, C. Botuha, A. Karaiskou, M. Salmain, J. Sobczak-Thépot, *Dalton Trans.* **2020**, *49*, 17635.

[63] E. Alessio, *Chem. Rev.* **2004**, *104*, 4203.

[64] S. Infante-Tadeo, V. Rodríguez-Fanjul, C. C. Vequi-Suplicy, A. M. Pizarro, *Inorg. Chem.* **2022**, *61*, 18970.

[65] A. Vázquez, R. Dzijak, M. Dračínský, R. Rampmaier, S. J. Siegl, M. Vrabel, *Angew. Chem. Int. Ed.* **2017**, *56*, 1334.

[66] S. Eising, B.-T. Xin, F. Kleinpenning, J. J. A. Heming, B. I. Florea, H. S. Overkleeft, K. M. Bonger, *ChemBioChem* **2018**, *19*, 1648.

[67] F. Liu, Y. Liang, K. N. Houk, *J. Am. Chem. Soc.* **2014**, *136*, 11483.

[68] A. Turlik, K. N. Houk, D. Svatunek, *J. Org. Chem.* **2021**, *86*, 13129.

[69] D. Svatunek, M. Wilkovitsch, L. Hartmann, K. N. Houk, H. Mikula, *J. Am. Chem. Soc.* **2022**, *144*, 8171.
<figure><img src="image_22.png" /></figure>

[70] J. W. Wijnen, S. Zavarise, J. B. F. N. Engberts, M. Charton, *J. Org. Chem.* **1996**, *61*, 2001.

[71] J. Stefanowicz-Hajduk, J. R. Ochocka, *Toxicol. Rep.* **2020**, *7*, 335.

[72] L. Guo, P. Li, Z. Jing, Y. Gong, K. Lai, H. Fu, H. Dong, Z. Yang, Z. Liu, *J. Inorg. Biochem.* **2024**, *258*, 112631.

[73] X. Ge, S. Chen, X. Liu, Q. Wang, L. Gao, C. Zhao, L. Zhang, M. Shao, X.-A. Yuan, L. Tian, Z. Liu, *Inorg. Chem.* **2019**, *58*, 14175.

[74] S. Chen, X. Liu, X. Ge, Q. Wang, Y. Xie, Y. Hao, Y. Zhang, L. Zhang, W. Shang, Z. Liu, *Inorg. Chem. Front.* **2020**, *7*, 91.

[75] L. Wang, X. Liu, Y. Wu, X. He, X. Guo, W. Gao, L. Tan, X.-A. Yuan, J. Liu, Z. Liu, *Inorg. Chem.* **2023**, *62*, 3395.

[76] X. Liu, C. Ji, R. Tao, W. Zheng, M. Liu, S. Bi, Q. Chang, X.-A. Yuan, M. Yue, Z. Liu, *J. Inorg. Biochem.* **2025**, *263*, 112792.

[77] M. Stilgenbauer, A. M. D. S. Jayawardhana, P. Datta, Z. Yue, M. Gray, F. Nielsen, D. J. Bowers, H. Xiao, Y.-R. Heng, *Chem. Commun.* **2019**, *55*, 6106.

[78] A. Annunziata, P. Imbimbo, M. E. Cucciolito, G. Ferraro, V. Langellotti, A. Marano, M. Melchiorre, G. Tito, M. Trifuoggi, D. M. Monti, A. Merlino, F. Ruffo, *Int. J. Mol. Sci.* **2023**, *24*, 2369.

[79] S. Imstepf, V. Pierroz, R. Rubbiani, M. Felber, T. Fox, G. Gasser, R. Alberto, *Angew. Chem. Int. Ed.* **2016**, *55*, 2792.

[80] M. Wenzel, A. Casini, *Coord. Chem. Rev.* **2017**, *352*, 432.

[81] *Medicinal Organometallic Chemistry* (Eds: G. Jaouen, N. Metzler-Nolte), Springer Berlin Heidelberg, Berlin, Heidelberg **2010**.

[82] R. N. V. Krishna Deepak, B. Chandrakar, R. Sankararamakrishnan, *Biophys. Chem.* **2017**, *224*, 32.

[83] S. Lin, X. Yang, S. Jia, A. M. Weeks, M. Hornsby, P. S. Lee, R. V. Nichiporuk, A. T. Iavarone, J. A. Wells, F. D. Toste, C. J. Chang, *Science* **2017**, *355*, 597.

[84] L. Zhong, A. Holmgren, *J. Biol. Chem.* **2000**, *275*, 18121.

[85] Y. Qi, Z. Liu, H. Li, P. J. Sadler, P. B. O'Connor, *Rapid Commun. Mass Spectrom.* **2013**, *27*, 2028.

[86] J. Will, D. A. Wolters, W. S. Sheldrick, *ChemMedChem* **2008**, *3*, 1696.

[87] F. Arnesano, S. Scintilla, G. Natile, *Angew. Chem. Int. Ed.* **2007**, *46*, 9062.

[88] C. A. Puckett, R. J. Ernst, J. K. Barton, *Dalton Trans.* **2010**, *39*, 1159.

[89] P. M. S. D. Cal, R. F. M. Frade, C. Cordeiro, P. M. P. Gois, *Chem. Eur. J.* **2015**, *21*, 8182.

[90] R. van Geel, G. J. M. Pruijn, F. L. van Delft, W. C. Boelens, *Bioconjug. Chem.* **2012**, *23*, 392.

[91] M. Huynh, R. Vinck, B. Gibert, G. Gasser, *Adv. Mater.* **2024**, *36*, 2311437.

[92] J. J. Conesa, A. C. Carrasco, V. Rodriguez-Fanjul, Y. Yang, J. L. Carrascosa, P. Cloetens, E. Pereiro, A. M. Pizarro, *Angew. Chem. Int. Ed.* **2020**, *59*, 1270.

[93] D. Guzman-Villanueva, M. R. Mendiola, H. X. Nguyen, F. Yambao, N. Yu, V. Weissig, in *Pharm. Nanotechnol. Basic Protoc.* (Eds.: V. Weissig, T. Elbayoumi), Springer New York, New York, NY **2019**, pp. 183–189.

[94] J. Li, L. Guo, Z. Tian, S. Zhang, Z. Xu, Y. Han, R. Li, Y. Li, Z. Liu, *Inorg. Chem.* **2018**, *57*, 13552.

[95] C. Li, M. Yu, Y. Sun, Y. Wu, C. Huang, F. Li, *J. Am. Chem. Soc.* **2011**, *133*, 11231.

[96] C. Li, Y. Liu, Y. Wu, Y. Sun, F. Li, *Biomaterials* **2013**, *34*, 1223.

Manuscript received: February 5, 2025

Revised manuscript received: April 2, 2025

Version of record online: April 14, 2025